RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Intra-Cellular Therapies Liabilities 2024

Intra-Cellular Therapies Liabilities

136.87 M USD

Intra-Cellular Therapies Dividend yield

Ticker

ITCI

ISIN

US46116X1019

WKN

A1XDTL

In 2024, Intra-Cellular Therapies's total liabilities amounted to 136.87 M USD, a 38.67% difference from the 98.7 M USD total liabilities in the previous year.

Intra-Cellular Therapies Aktienanalyse

What does Intra-Cellular Therapies do?

Intra-Cellular Therapies Inc is a biopharmaceutical company that focuses on developing innovative therapies for mental disorders and other severe diseases. The company was founded in 2002 in New York City and is now headquartered in Montvale, New Jersey. Intra-Cellular Therapies' business model is based on identifying and researching novel compounds that target the restoration of balance of certain neurotransmitters in the brain. The company has a wide range of technologies and development programs to validate and optimize its therapy approaches. Intra-Cellular Therapies operates in two main business areas: neurology and oncology. However, the company's focus is on developing compounds for mental disorders such as schizophrenia, bipolar disorder, or depression. One of the company's main compounds is Lumateperone, a new medication for the treatment of schizophrenia. Lumateperone has shown promising results in clinical studies and has the potential to provide significant improvement for patients with schizophrenia, particularly in terms of cognitive function and the negative symptom profile. Intra-Cellular Therapies is currently working on the approval of Lumateperone by the US Food and Drug Administration (FDA). Another important compound is ITI-007, a non-sedative atypical antipsychotic that aims to restore the balance of dopamine and serotonin in the brain. The substance has shown superior efficacy over standard medications in clinical studies and could be a new treatment option for patients with bipolar disorder and schizophrenia. Intra-Cellular Therapies plans to launch ITI-007 in the coming years. In addition to neurology, Intra-Cellular Therapies is also developing compounds for oncology. The company's main compound in this area is ITI-333, a novel inhibitor of the protein Factor VIIa, which could be used as a potential cancer therapy. ITI-333 is currently in preclinical development. In the past years, Intra-Cellular Therapies has made significant progress in developing new compounds and now has a promising product pipeline. The company has also formed partnerships with other pharmaceutical companies such as Bristol-Myers Squibb and Takeda Pharmaceuticals to further strengthen its technologies and development programs. Overall, Intra-Cellular Therapies Inc has established itself as one of the leading innovators in the field of neuropsychiatry and could play a significant role in the development of new therapeutics for mental disorders and other severe diseases in the coming years. Intra-Cellular Therapies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Intra-Cellular Therapies's Liabilities

Intra-Cellular Therapies's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Intra-Cellular Therapies's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Intra-Cellular Therapies's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Intra-Cellular Therapies's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Intra-Cellular Therapies’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Intra-Cellular Therapies Stock

What is the level of liabilities of Intra-Cellular Therapies this year?

Intra-Cellular Therapies has a debt balance of 136.87 M USD this year.

What were the liabilities of Intra-Cellular Therapies compared to the previous year?

The liabilities of Intra-Cellular Therapies have increased by 38.67% increased compared to the previous year.

What are the consequences of high debt for investors of Intra-Cellular Therapies?

High liabilities can pose a risk for investors of Intra-Cellular Therapies, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Intra-Cellular Therapies?

Low liabilities mean that Intra-Cellular Therapies has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Intra-Cellular Therapies affect the company?

An increase in liabilities of Intra-Cellular Therapies can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Intra-Cellular Therapies affect the company?

A decrease in the liabilities of Intra-Cellular Therapies can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Intra-Cellular Therapies?

Some factors that can influence the liabilities of Intra-Cellular Therapies include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Intra-Cellular Therapies so important for investors?

The liabilities of Intra-Cellular Therapies are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Intra-Cellular Therapies take to modify the liabilities?

To change its liabilities, Intra-Cellular Therapies can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Intra-Cellular Therapies pay?

Over the past 12 months, Intra-Cellular Therapies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Intra-Cellular Therapies is expected to pay a dividend of 0 USD.

What is the dividend yield of Intra-Cellular Therapies?

The current dividend yield of Intra-Cellular Therapies is .

When does Intra-Cellular Therapies pay dividends?

Intra-Cellular Therapies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Intra-Cellular Therapies?

Intra-Cellular Therapies paid dividends every year for the past 0 years.

What is the dividend of Intra-Cellular Therapies?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Intra-Cellular Therapies located?

Intra-Cellular Therapies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Intra-Cellular Therapies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Intra-Cellular Therapies from 5/25/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 5/25/2024.

When did Intra-Cellular Therapies pay the last dividend?

The last dividend was paid out on 5/25/2024.

What was the dividend of Intra-Cellular Therapies in the year 2023?

In the year 2023, Intra-Cellular Therapies distributed 0 USD as dividends.

In which currency does Intra-Cellular Therapies pay out the dividend?

The dividends of Intra-Cellular Therapies are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Intra-Cellular Therapies stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Intra-Cellular Therapies

Our stock analysis for Intra-Cellular Therapies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Intra-Cellular Therapies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.